Compare Crispr Therapeutics AG (CRSP) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares MSCI United Kingdom (FTSE) — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and iShares MSCI United Kingdom (FTSE) is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares MSCI United Kingdom (FTSE) for 46 Days on average.
| CRSP | EWU | |
|---|---|---|
Market Cap | $4.88B | $3.62B |
Volume | 2,861,747 | 923,896 |
Sector | Health | Broad Market / Factor |
52-Week High | $74.92 | $49.39 |
52-Week Low | $44.34 | $41.34 |
Typical Hold Time | 77 Days | 46 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
EWU is trading at $46.52, up 1.28% today, but faces significant technical headwinds with a bearish overall signal. The stock shows mixed technical indicators with oversold RSI levels but strong bearish momentum signals from ADX. Recent UK market volatility, driven by rising gilt yields and inflation concerns, creates a challenging environment for this UK-focused ETF.
The outlook remains cautious as UK economic pressures mount, with rising borrowing costs and energy price inflation creating headwinds. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include continued UK market volatility and persistent inflation pressures that could pressure UK equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →
